Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Time to Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLFGet Free Report)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $14.61, but opened at $15.37. Ono Pharmaceutical shares last traded at $15.37, with a volume of 7,520 shares.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, Ono Pharmaceutical currently has a consensus rating of “Strong Buy”.

Read Our Latest Stock Report on OPHLF

Ono Pharmaceutical Stock Up 1.7%

The business’s 50 day moving average price is $14.34 and its 200 day moving average price is $14.79. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56. The firm has a market cap of $6.98 billion, a PE ratio of 14.15 and a beta of 0.33.

Ono Pharmaceutical Company Profile

(Get Free Report)

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.

Recommended Stories

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.